<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03032458</url>
  </required_header>
  <id_info>
    <org_study_id>MD/16.11.72</org_study_id>
    <nct_id>NCT03032458</nct_id>
  </id_info>
  <brief_title>Efficacy of Pethidine, Ketorolac And Xylocaine Gel As Analgesics For Pain Control In Shockwave Lithotripsy</brief_title>
  <official_title>Efficacy of Pethidine, Ketorolac And Xylocaine Gel As Analgesics For Pain Control In Shockwave Lithotripsy Single Blinded Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised prospective trial comparing the efficacy of pethidine, Ketorolac, and Xylocaine
      gel as analgesics for pain control in shockwave lithotripsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pain perception during shockwave lithotripsy (SWL) is affected by patient-related factors
      like age, gender, and body habitus moreover, young female patients, anxious and depressed
      patients or thin patients experience more pain during SWL.

      Several physical variables influencing treatment-related pain have been identified: the type
      of the shockwave source, size, and site of stone burden, peak pressure of the shockwaves,
      diameter of the focal zone, and size of the aperture of the shockwave source reflecting the
      area of shockwave entry at the skin.

      Pain relief during SWL is vital, not only to maintain patient comfort and satisfaction, but
      also to facilitate stone imaging and targeting by reducing patients' movements during
      successive shock wave impacts. Reduced patient movement enables increase fragmentation
      efficiency and reduce the risk of procedure-related morbidity. So, a relaxed, cooperative
      patient during treatment is paramount in maintaining stone targeting for optimal
      fragmentation.

      Across 21 centers in the United Kingdom (UK), 17 distinct analgesia regimens were reported in
      SWL analgesia practice.

      In 2016 European Association of Urology (EUA) guidelines for SWL Pain control stated that
      pain control during SWL is necessary to limit pain induced movements and excessive
      respiratory excursions, However no recommendation for proper analgesia in contrast to clear
      recommendation for Pain relief in patients with an acute stone episode.

      The investigators will try in this trial to identify the best efficacious type of analgesia
      for patient during SWL in this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain control __ Outcome Measure by &quot;pain assessment scales of The National Initiative on Pain Control™ (NIPC™)&quot;</measure>
    <time_frame>10 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of anxiety on success of SWL __ Outcome Measure by &quot;Generalized Anxiety Disorder 7-item &quot;</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of anxiety on success of SWL __ Outcome Measure by &quot;The Patient Health Questionnaire (PHQ-9)&quot;</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare stone free rate __ Outcome Measure by &quot;ultrasound and plain x-ray&quot; 1 week after session. If no residual stone, NCCT scan.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Analgesia</condition>
  <condition>Urolithiasis</condition>
  <arm_group>
    <arm_group_label>Pethidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pethidine 25 mg IV bolus (Pethidine hydrochloride 50mg ampule, Roche Pharmaceutical Company - Egypt)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketolac 30 mg (ketorolac, Amriya Pharmaceutical Industries - Egypt)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Xylocaine Gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Xylocaine gel (lidocaine 2%, AstraZeneca Pharmaceutical Company - Egypt)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pethidine</intervention_name>
    <description>pethidine 25 mg IV bolus injection before start of session plus placebo gel then then IV infusion, so that the total dose doesn't exceed 1mg/kg</description>
    <arm_group_label>Pethidine</arm_group_label>
    <other_name>Pethidine 50</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>ketorolac IV bolus injection before start of session plus placebo gel then 30 mg IV infusion so that total dose doesn't exceed 60 mg.</description>
    <arm_group_label>Ketorolac</arm_group_label>
    <other_name>Ketolac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xylocaine Gel</intervention_name>
    <description>Xylocaine gel locally 15 minutes before session with 10 mg normal saline IV bolus before session then IV normal saline infusion then</description>
    <arm_group_label>Xylocaine Gel</arm_group_label>
    <other_name>lidocaine 2%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with renal and upper ureteral stones amenable to SWL.

        Exclusion Criteria:

          -  Allergy to pethidine.

          -  Allergy to Ketorolac.

          -  Allergy to Xylocaine gel.

          -  American Society of Anesthesiologists score ≥ 3 (ASA III or more).

          -  Pregnancy.

          -  Patients with a pacemaker.

          -  Bleeding diatheses.

          -  Uncontrolled urinary tract infection (UTI).

          -  Severe obesity which prevent targeting of the stone.

          -  Body Mass IndexBMI (40 or more)

          -  Arterial aneurysm in the vicinity of the stone.

          -  Anatomical obstruction distal to the stone.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hassan Abol-Enein, MD, Phd</last_name>
    <role>Study Chair</role>
    <affiliation>Urology and Nephrology Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Urology and Nephrology Center</name>
      <address>
        <city>Mansourah</city>
        <state>Aldakahlia</state>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2017</study_first_submitted>
  <study_first_submitted_qc>January 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2017</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Abdelwahab Hashem</investigator_full_name>
    <investigator_title>Urology Msc, Oncology fellow at Urology and Nephrology Center, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Shock Wave Lithotripsy</keyword>
  <keyword>Ketorolac</keyword>
  <keyword>Xylocaine Gel</keyword>
  <keyword>Pethidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Meperidine</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>meta-analyses by contact the Prof. Hassan Abol-Enein, MD, Phd (Study Chair) or Prof. Khaled Z. Sheir, MD ( Study Central Contact Backup)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

